AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

In vivo production of CAR T cell: Opportunities and challenges

Zhiqiang Songa,b,1, Yi Zhoua,1, Binbin Wanga,1, Yuke Genga,c,1, Gusheng Tanga( ), Yang Wanga( ), Jianmin Yanga( )
Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China
Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200433, China
Department of Oncology, No. 970th Hospital of Joint Logistic Support Force of PLA, Yantai, Shandong 264000, China

1 These authors contributed equally to this work.

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).

Show Author Information

Abstract

Chimeric antigen receptor T (CAR T) cell therapy has achieved remarkable efficacy for patients with hematological malignancies. However, in vitro viral vector-mediated production of CAR T cells is time-consuming and expensive and impairs T cell function. On one hand, an elaborate manufacturing process not only impairs the function of CAR T cells but also limits its usage in patients with rapidly progressing diseases. On the other hand, high costs are incompatible with broad clinical applications for sizable populations. In vivo production of CAR T cells is a novel approach that can avoid complicated production processes and reduce costs through mass production. Additionally, in vivo production of CAR T cells does not damage the function of T cells compared with in vitro production. Early studies have demonstrated promising antitumor activity of in vivo CAR T cell therapy in preclinical models of hematological malignancies. In this review, we describe the latest developments of in vivo CAR T cell therapy and discuss its potential challenges for clinical application.

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101612

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Song Z, Zhou Y, Wang B, et al. In vivo production of CAR T cell: Opportunities and challenges. Genes & Diseases, 2025, 12(6): 101612. https://doi.org/10.1016/j.gendis.2025.101612

906

Views

6

Downloads

15

Crossref

21

Web of Science

25

Scopus

1

CSCD

Received: 28 August 2024
Revised: 09 January 2025
Accepted: 23 February 2025
Published: 25 March 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).